NCT06109376

Brief Summary

Reducing or suspending the increase of the infarcted core, i.e., "freezing" the ischemic penumbra, may help improve the efficacy of mechanical thrombectomy. Hypothermia effectively reduces the metabolic level of brain tissue, may prolong the time window for recanalization therapy, and its multi-target therapeutic effect make it one of the most promising neuro-protection approach. In recent years, hypothermia has been increasingly used to treat acute ischemic stroke. However, its role in acute ischemic stroke is unclear. The objective of this trial is to investigate whether hypothermia combined with endovascular thrombectomy could add additional benefit without increasing the risk of adverse events such as pneumonia, intracerebral hemorrhage, and mortality.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
11mo left

Started Dec 2023

Longer than P75 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress73%
Dec 2023Mar 2027

First Submitted

Initial submission to the registry

October 22, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

October 31, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

December 1, 2023

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2027

Last Updated

October 31, 2023

Status Verified

October 1, 2023

Enrollment Period

3.1 years

First QC Date

October 22, 2023

Last Update Submit

October 25, 2023

Conditions

Keywords

endovascular thrombectomyhypothermialarge vessel occlusionrandomized controlled trial

Outcome Measures

Primary Outcomes (1)

  • Modified Rankin scale score (mRS)

    Modified Rankin scale score (mRS): scores range from 0 to 6, with 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death

    90 days post-randomization

Secondary Outcomes (15)

  • Excellent outcome

    90 days post-randomization

  • Functional independence

    90 days post-randomization

  • Moderate outcome

    90 days post-randomization

  • Early neurological improvement

    72 hours post-randomization

  • EQ-5D-5L scale score

    90 days post-randomization

  • +10 more secondary outcomes

Study Arms (2)

Hypothermia

EXPERIMENTAL

Patients in Hypothermia group received hypothermia combined with endovascular thrombectomy.

Procedure: hypothermiaProcedure: thrombectomy

Control

ACTIVE COMPARATOR

Patients in Control group received endovascular thrombectomy alone.

Procedure: thrombectomy

Interventions

hypothermiaPROCEDURE

In this trial, intra-arterial select cooling infusion is used to reduce brain tissue temperature to 33-35°C.

Hypothermia
thrombectomyPROCEDURE

Thrombectomy includes treatment with stent retrievers and/or thromboaspiration, balloon angioplasty, stenting, intra-arterial thrombolysis, or the various combinations of these approaches.

ControlHypothermia

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged ≥ 18 years or more;
  • acute ischemic stroke within 24 hours from onset to randomization;
  • NIHSS ≥6 points before randomization;
  • Internal carotid artery, or the middle cerebral artery M1 or M2 occlusion confirmed by CTA/MRA/DSA;
  • Baseline ASPECTS score ≥ 3 and ≤8, or cerebral infarction core volume \< 100ml;
  • The patient decides to undergo endovascular therapy;
  • The patient or patient's representative signs a written informed consent form.

You may not qualify if:

  • CT or MR evidence of hemorrhage;
  • Currently pregnant or lactating (women patients);
  • Allergy to radiographic contrast agents, or nitinol devices;
  • Arterial tortuosity and/or other arterial disease that would prevent the device from reaching the target vessel;
  • Multiple vessel occlusion (e.g., bilateral anterior circulation, or occlusion of both anterior and posterior circulation);
  • Preexisting neurological or psychiatric disease that would confound the neurological functional evaluations;
  • Previous bleeding disorders, severe heart, liver or kidney disease, or sepsis;
  • Brain tumors with mass effect (except meningiomas) that are radiographically pleasant;
  • Intracranial aneurysm, arteriovenous malformation;
  • Any terminal illness with life expectancy less than 6 months;
  • Participating in other clinical trials.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Ischemic StrokeHypothermia

Interventions

Thrombectomy

Condition Hierarchy (Ancestors)

StrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesBody Temperature ChangesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Vascular Surgical ProceduresCardiovascular Surgical ProceduresSurgical Procedures, Operative

Central Study Contacts

Guangxiong Yuan, M.S.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

October 22, 2023

First Posted

October 31, 2023

Study Start

December 1, 2023

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

March 31, 2027

Last Updated

October 31, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will share

Study Protocol, Statistical Analysis Plan, Informed Consent Form, Clinical Study Report, and Analytic Code will be shared after approval of a proposal from principal investigator 3 years after the trial results are revealed.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
3 years after the trial results are revealed.
Access Criteria
after approval of a proposal from principal investigator